Insights
Insights on health, access and innovation
Read practical thinking from Newmarket Strategy on the policy, access, reimbursement and health system issues shaping healthcare and life sciences.
The continuing rise of biosimilars in the UK
The entrance of biosimilar competitors into a therapeutic area is an ever-present concern for pharmaceutical companies managing ageing product portfolios. On the other hand, any potential benefit to patients and…
UK government publishes new draft data strategy
The government has this week published the long-awaited draft data strategy: Data saves lives: reshaping health and social care with data. This new strategy builds upon previous attemptsto harness the NHS’s rich store of patient…
Femtech – the way forward for women?
At the beginning of April, many European nations halted their vaccination programme in fears that the Oxford-AstraZeneca Covid-19 vaccine increased the recipient’s chances of developing severe and deadly blood clots.…
NICE’s Changing Role: a win for NICE, if it can deliver
First in a series of articles considering the implications of NICE’s changing role for industry and patients. NICE’s role and remit has grown and morphed over its twenty plus year history,…
Same challenges, new opportunities – the impact for industry of the Commercial Framework for New Medicines
As any experienced market access professional will tell you, securing access to a new medicine is rarely as simple as just submitting a dossier to a national body and waiting for a positive recommendation. Behind the…
Bringing in Change with Brexit
There is no doubting the importance of the Brexit trade deal, given how closely linked the EU and the UK markets are. There are enormous numbers involved; every month at least 45 million packs of medicines are…
Events
